Sort   by:  
 Page size 
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownStratified analyses refine association between TLR7 rare variants and severe COVID-19.
Not available
S-EPMC11320601 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownGWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Not available
S-EPMC10208981 | biostudies-literature
UnknownConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownWhole-genome sequencing reveals host factors underlying critical COVID-19.
Not available
S-EPMC9259496 | biostudies-literature
Sort   by:  
 Page size